Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790516 · ClinicalTrials.gov registry record · NA
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
A NA study, sponsored by Georgetown University.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01790516 is a NA study that was terminated before completion, run by Georgetown University. The registered enrollment target is 2 participants.
The verdict
NCT01790516, a NA study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is for patients with newly diagnosed head and neck cancer that cannot be removed by surgery. The purpose of this study is to determine the feasibility of using genetic variations in patients to select the right drug to treat head and neck cancer. Cisplatin and cetuximab (Erbitux)are both approved by the FDA to treat head and neck cancer in combination with radiation therapy. In this study the investigators will test whether genetic differences between patients can be used to pick which of these two drugs a patient should receive. All patients will have a blood sample drawn that will be tested for genetic differences. If patients have genetic differences that correlate with a better outcome from cisplatin they will receive cisplatin with radiation. If patients have genetic differences that do not correlate with a better outcome from cisplatin they will receive cetuximab with their radiation therapy.
Interventions
- DRUG Cisplatin
- DRUG cetuximab
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790516
The ClinicalTrials.gov registry entry for NCT01790516 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01790516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01790516 about?
NCT01790516 is a clinical study titled "Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer". This study is for patients with newly diagnosed head and neck cancer that cannot be removed by surgery. The purpose of this study is to determine the feasibility of using genetic variations in patients to select the right drug to treat head and neck cancer. Cisplatin and cetuximab (Erbitux)are both...
What is the current status of trial NCT01790516?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2012-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01790516?
The interventions under investigation include: Cisplatin (DRUG), cetuximab (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT01790516?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.